Media headlines about Marinus Pharmaceuticals (NASDAQ:MRNS) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Marinus Pharmaceuticals earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.4002372955761 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several equities analysts recently issued reports on the company. Laidlaw assumed coverage on Marinus Pharmaceuticals in a report on Thursday, December 14th. They set a “buy” rating and a $18.00 price objective for the company. BidaskClub raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. Mizuho assumed coverage on Marinus Pharmaceuticals in a report on Monday, March 19th. They set a “buy” rating and a $13.00 price objective for the company. Finally, HC Wainwright assumed coverage on Marinus Pharmaceuticals in a report on Thursday, February 15th. They set a “buy” rating and a $33.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $18.75.
Shares of NASDAQ MRNS traded down $0.07 during trading on Friday, reaching $4.08. The company had a trading volume of 389,707 shares, compared to its average volume of 1,247,680. Marinus Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $9.87.
In other news, CEO Christopher Michael Cashman sold 9,566 shares of the business’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $6.28, for a total value of $60,074.48. Following the completion of the transaction, the chief executive officer now directly owns 247,903 shares of the company’s stock, valued at $1,556,830.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3341503/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-marinus-pharmaceuticals-mrns-stock-price.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.